Section 58
Chapter 57,743

Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase Ii study (JSCT-NHL04)

Murayama, T.; Fukuda, T.; Okumura, H.; Sunami, K.; Sawazaki, A.; Maeda, Y.; Tsurumi, H.; Uike, N.; Hidaka, T.; Takatsuka, Y.; Eto, T.; Tsuda, H.; Fujisaki, T.; Miyamoto, T.; Tsuneyoshi, N.; Iyama, S.; Nagafuji, K.; Harada, M.

International Journal of Hematology 103(6): 676-685


ISSN/ISBN: 1865-3774
PMID: 27084252
DOI: 10.1007/s12185-016-1976-4
Accession: 057742050

Download citation:  

To evaluate the efficacy and feasibility of upfront high-dose chemotherapy (HDCT) and rituximab (R) followed by autologous peripheral blood stem cell transplantation (auto-PBSCT) in patients with newly diagnosed high-intermediate(HI)-, and high(H)-risk diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter prospective phase II trial. In 15-60-year-old patients with H- or HI-risk DLBCL, after three courses of (R-)CHOP14, high-dose etoposide was given prior to peripheral blood stem cell harvesting. After an additional three courses of (R-)CHOP14, auto-PBSCT was performed following HDCT. The primary endpoint of the study is progression-free survival (PFS) at 2 years after registration in eligible patients. The expected PFS and the threshold PFS were estimated to be 70 and 50 %, respectively. Among 40 eligible patients registered, 30 patients completed treatment. With a median observation period in surviving eligible patients of 63 months, the 2- and 4-year PFS after registration were 79.9 and 72.0 %, respectively. The 2- and 4-year overall survival (OS) were 92.5 and 84.6 %, respectively. In 30 patients who completed treatment, the 4-year PFS and OS after auto-PBSCT were 79.2 and 85.9 %, respectively. In conclusion, the results of our study suggest that upfront HDCT and auto-PBSCT combined with rituximab is highly effective as an initial treatment for HI-, and H-risk DLBCL.

PDF emailed within 0-6 h: $19.90